Results 31 to 40 of about 15,200 (191)

Efficacy and safety of daratumumab combined with all-trans retinoic acid in relapsed/refractory multiple myeloma [PDF]

, 2021
The efficacy of daratumumab depends partially on CD38 expression on multiple myeloma (MM) cells. We have previously shown that all-trans retinoic acid (ATRA) upregulates CD38 expression and reverts daratumumab-resistance ex vivo.
Bos, Gerard M.J., Broijl, Annemiek, Frerichs, Kristine A., Kersten, Marie Jose, Klein, Saskia K., Levin, Mark David, Maas-Bosman, Patricia W.C., Minnema, Monique C., Mutis, Tuna, Nijhof, Inger S., Sonneveld, Pieter, Van de Donk, Niels W.C.J., Verkleij, Christie P.M., Zweegman, Sonja   +13 more
core   +4 more sources

Subcutaneous daratumumab in Chinese patients with relapsed or refractory multiple myeloma: an open-label, multicenter, phase 1 study (MMY1010)

Blood Science
Despite recent progress in multiple myeloma (MM) treatments, most patients will relapse and require additional treatment. Intravenous daratumumab, a human IgGκ monoclonal antibody targeting CD38, has shown good efficacy in the treatment of MM.
Gang An, Zheng Ge, Hongmei Jing, Jing Liu, Guoping Yang, Ru Feng, Zhongyuan Xu, Ming Qi, Jianping Wang, Juanjuan Song, Wei Zhou, Binbin Sun, Dian Zhu, Xi Chen, Canchan Cui, Lugui Qiu   +15 more
doaj   +1 more source

Efficacy and safety of melflufen plus daratumumab and dexamethasone in relapsed/refractory multiple myeloma: results from the randomized, open-label, phase III LIGHTHOUSE study

Haematologica, 2023
Melphalan flufenamide (melflufen), a first-in-class alkylating peptide-drug conjugate, plus dexamethasone was approved in Europe for use in patients with triple-class refractory relapsed/refractory multiple myeloma (RRMM) with ≥3 prior lines of therapy ...
Luděk Pour, Monika Szarejko, Jelena Bila, Fredrik H. Schjesvold, Ivan Spicka, Vladimir Maisnar, Artur Jurczyszyn, Zhanet Grudeva-Popova, Roman Hájek, Ganna Usenko, Marcus Thuresson, Stefan Norin, Sara Jarefors, Nicolaas A. Bakker, Paul G. Richardson, Maria-Victoria Mateos   +15 more
doaj   +1 more source

Hulgimüeloomi ravi [PDF]

, 2016
Hematoloogiliste kasvajate esinemise korral on 10–15%-l juhtudest tegu müeloomtõvega (1). Müeloomtõbi ei ole väljaravitav, kuid ravimitega on võimalik aeglustada haiguse progresseerumist, parandada patsientide elukvaliteeti ning pikendada elu. Viie aasta
Hein, Marju, Pintson, Madli
core   +2 more sources

Determining therapeutic susceptibility in multiple myeloma by single-cell mass accumulation [PDF]

, 2017
Multiple myeloma (MM) has benefited from significant advancements in treatment that have improved outcomes and reduced morbidity. However, the disease remains incurable and is characterized by high rates of drug resistance and relapse.
Calistri, Nicholas L, Cetin, Arif Engin, Kimmerling, Robert John, Manalis, Scott R, Olcum, Selim A., Stevens, Mark M.   +5 more
core   +1 more source

The real-world outcomes of multiple myeloma patients treated with daratumumab.

PLoS ONE, 2021
Most patients cannot be included in randomized clinical trials. We report real-world outcomes of all Danish patients with multiple myeloma (MM) treated with daratumumab-based regimens until 1 January 2019.MethodsInformation of 635 patients treated with ...
Agoston Gyula Szabo, Tobias Wirenfeldt Klausen, Mette Bøegh Levring, Birgitte Preiss, Carsten Helleberg, Marie Fredslund Breinholt, Emil Hermansen, Lise Mette Rahbek Gjerdrum, Søren Thorgaard Bønløkke, Katrine Nielsen, Eigil Kjeldsen, Katrine Fladeland Iversen, Elena Manuela Teodorescu, Marveh Dokhi, Eva Kurt, Casper Strandholdt, Mette Klarskov Andersen, Annette Juul Vangsted   +17 more
doaj   +1 more source

ARQ-197, a small-molecule inhibitor of c-Met, reduces tumour burden and prevents myeloma-induced bone disease in vivo [PDF]

, 2018
The receptor tyrosine kinase c-Met, its ligand HGF, and components of the downstream signalling pathway, have all been implicated in the pathogenesis of myeloma, both as modulators of plasma cell proliferation and as agents driving osteoclast ...
Buckle, C.H., Chantry, A.D., Down, J.M., Evans, H.R., Fisher, M., Lath, D.L., Lawson, M.A.   +6 more
core   +2 more sources

CD200 immune checkpoint expression is associated with inferior outcome in multiple myeloma patients treated with anti-CD38 monoclonal antibodies

OncoImmunology
In multiple myeloma (MM), the anti-CD38 monoclonal antibody Daratumumab has become essential in the therapeutic arsenal, although very few predictive factors of response to Daratumumab have been identified in clinical studies.
Djamila Chemlal, Camille Pochard, Valentin Jacquier, Angélique Bruyer, Ludovic Gabellier, Léa Fornero, Clément Vempère, Amélie Machura, Guilhem Requirand, Nicolas Robert, Caroline Bret, Guillaume Cartron, Laure Vincent, Hugues de Boussac, Jérôme Moreaux, Charles Herbaux   +15 more
doaj   +1 more source

Daratumumab for treatment‐refractory antibody‐mediated diseases in neurology [PDF]

, 2022
Background and purpose A fraction of patients with antibody-mediated autoimmune diseases remain unresponsive to first-/second-line and sometimes even to escalation immunotherapies.
Alexander, Tobias, Aschman, Tom, Blau, Igor‐Wolfgang, Hoffmann, Sarah, Meisel, Andreas, Meisel, Christian, Ostendorf, Lennard, Prüss, Harald, Radbruch, Helena, Scheibe, Franziska   +9 more
core   +1 more source

Minimal Residual Disease Assessment in the Context of Multiple Myeloma Treatment [PDF]

, 2016
With contemporary therapeutic strategies in multiple myeloma, heretofore unseen depth and rate of responses are being achieved. These strategies have paralleled improvements in outcome of multiple myeloma patients.
Jinming Song, Kenneth H. Shain, Taiga Nishihori   +2 more
core   +1 more source